Skip to content

Corporate Policies

Alt Text Required

Corporate Policies

Illumina corporate policies outline how our business principles align with our core values, ethical responsibilities, and legal obligations. These policies demonstrate our commitment to operate with the highest standards of excellence, while delivering integrated solutions that advance the understanding of genetics and health.

Compliance Program

Illumina is committed to conducting its business in compliance with all applicable laws and regulations, and with the highest ethical standards. Based on this commitment, our Board of Directors has adopted this Code of Conduct that applies to all of our employees, consultants, temporary workers, officers, and members of the Board of Directors, regardless of location, seniority level, business unit, function, or region. The Code of Conduct includes various topics including fraud prevention, bribery & corruption, anti-discrimination, anti-harassment, marketing & sales claims and government interaction.

Oversight of Illumina’s Code of Conduct

We have established a Compliance Committee to direct and oversee our compliance activities, including administering the Code of Conduct. The Compliance Committee is comprised of senior executives, one of which is our Chief Compliance Officer. Our General Counsel has been designated as the Company’s Chief Compliance Officer.

Compliance Committee Charter
Compliance Committee Framework

Compliance Training

Illumina provides training on its Code of Conduct for new and existing employees as well as training on other company policies. Training is conducted through Illumina’s Learning Management System and training records are documented for all employees.

Ethics Advisory Board

Since 2008, Illumina appointed an Ethics Advisory Board (EAB) to ensure Illumina is practicing fair and ethical values. The EAB meets as necessary, but at least twice a year, to advise and provide recommendations regarding ethical issues involving Illumina’s existing, emerging, and prospective products, services, and processes both from a research and clinical perspective. This includes providing strategic advice to Illumina regarding emerging ethics issues, policies, and regulations that are relevant to the genomic industry.